Resin for solid phase synthesis of resin-bound unnatural amino acids is useful for distributed drug discovery, in which potential drug molecules can be produced by simple techniques
Polymer Laboratories has launched a new resin for the solid phase synthesis of resin-bound unnatural amino acids, one of the most commonly used intermediates in combinatorial chemistry, and peptides and peptidomimetics.
This resin, PL-Big-W resin (the benzophenone imine of Gly-Wang), is an addition to Polymer Laboratories's StratoSpheres product range.
The development of benzophenone imine of Gly-Wang has been pioneered by Professors William Scott and Martin O'Donnell from Indiana University Purdue University Indianapolis (IUPUI) for a concept they call 'distributed drug discovery'.
One of the principles behind distributed drug discovery is that many potential drug molecules can be produced by simple techniques, using inexpensive solid phase equipment, readily available starting materials and robust synthetic procedures.
Polymer Laboratories's PL-Big-W resin is the commercial source of the starting resin used by Scott and O'Donnell.
The company says its StratoSpheres resins are manufactured with exceptional batch to batch reproducibility, optimised particle sizes, and very high loadings for improved yield, economy and speed of operation.
These product characteristics contribute to a very high degree of product purity.
In the example of distributed drug discovery, students conduct reactions six at a time, in a combinatorial 3x2 grid (three alkylating agents and two acylating agents), with simple, inexpensive Bill-Board solid phase equipment from Leads Metal Products.
Starting with PL-Big-W resin, each student carries out a control synthesis (alkylation with benzyl bromide and acylation with Fmoc chloride) in one of these six positions.
Using the PL-Big-W resin, they routinely obtain the final product with an LC/MS analytical purity of 90-98%.
